BRPI0415001A - droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo - Google Patents
droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativoInfo
- Publication number
- BRPI0415001A BRPI0415001A BRPI0415001-5A BRPI0415001A BRPI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A
- Authority
- BR
- Brazil
- Prior art keywords
- acid
- drug
- active ingredient
- acid containing
- propyloctanoic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Details Of Rigid Or Semi-Rigid Containers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"DROGA CONTENDO áCIDO (2R) -2-PROPILOCTANóICO COMO O INGREDIENTE ATIVO". A presente invenção se refere a uma droga que contém de cerca de um a cerca de cinco equivalentes de um íon de metal básico fornecido a partir de um sal de metal de um ácido fraco ou de um hidróxido de metal por equivalente do ácido (2R)-2-propiloctanóico ou o sal do mesmo; que seja útil no tratamento de doenças neurodegenerativas, opcionalmente junto com outros aditivos. A droga acima descrita é uma droga de alta concentração que apresenta um valor de pH adequado para a administração intravenosa; é altamente tolerante a mudanças de pH e permanece transparente depois de diluída para o preparo de uma infusão, desta forma permitindo a preparação de uma injeção e assim por diante, com o uso de um solvente arbitrário e/ou fluido de diluição.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003345124 | 2003-10-03 | ||
PCT/JP2004/014892 WO2005032536A1 (ja) | 2003-10-03 | 2004-10-01 | (2r)−2−プロピルオクタン酸を有効成分とする薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0415001A true BRPI0415001A (pt) | 2006-11-07 |
Family
ID=34419441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415001-5A BRPI0415001A (pt) | 2003-10-03 | 2004-10-01 | droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo |
Country Status (21)
Country | Link |
---|---|
US (1) | US8053599B2 (pt) |
EP (1) | EP1669065B1 (pt) |
JP (1) | JP4715515B2 (pt) |
KR (1) | KR101144553B1 (pt) |
CN (1) | CN1889942B (pt) |
AU (1) | AU2004277826B2 (pt) |
BR (1) | BRPI0415001A (pt) |
CA (1) | CA2540670A1 (pt) |
EC (1) | ECSP066477A (pt) |
ES (1) | ES2390055T3 (pt) |
IL (1) | IL174655A0 (pt) |
IS (1) | IS8430A (pt) |
MA (1) | MA28142A1 (pt) |
MX (1) | MXPA06003533A (pt) |
NO (1) | NO20061460L (pt) |
NZ (1) | NZ546231A (pt) |
RU (1) | RU2388467C2 (pt) |
SG (1) | SG146687A1 (pt) |
TW (1) | TW200519080A (pt) |
WO (1) | WO2005032536A1 (pt) |
ZA (1) | ZA200602690B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200613009A (en) * | 2004-06-11 | 2006-05-01 | Ono Pharmaceutical Co | Capsule having chewing stability |
TWI462745B (zh) * | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
JP5541845B2 (ja) * | 2008-03-28 | 2014-07-09 | Jcrファーマ株式会社 | アトピー性皮膚炎治療剤 |
AU2009312235B2 (en) * | 2008-11-04 | 2014-01-16 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone |
CA2734284C (en) | 2008-11-20 | 2014-01-21 | Techno Guard Co., Ltd. | Pyrazolone derivative formulations |
JP5759804B2 (ja) * | 2011-06-27 | 2015-08-05 | 富士フイルム株式会社 | 容器詰製剤 |
JP2018052861A (ja) * | 2016-09-29 | 2018-04-05 | ノーベルファーマ株式会社 | ホスフェニトインナトリウム注射剤 |
WO2020128928A1 (en) * | 2018-12-19 | 2020-06-25 | Jafari Javid Mihan | A formulation for treatment of neurodegenerative and demyelinating and neuropathic disorders and a method for preparation thereof |
CN110441421B (zh) * | 2019-08-02 | 2022-09-09 | 聊城高新生物技术有限公司 | 一种高效液相色谱法测定恩他卡朋片溶出度的方法 |
CN112180095B (zh) * | 2020-06-04 | 2023-10-13 | 三诺生物传感股份有限公司 | 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法 |
IT202000015895A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | L’impiego di acido arundico nella terapia della sclerosi multipla |
AU2022280595A1 (en) * | 2021-05-26 | 2023-11-09 | Daewoong Pharmaceutical Co., Ltd. | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
CN113341019A (zh) * | 2021-06-09 | 2021-09-03 | 江西省药品检验检测研究院 | 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2113574T3 (es) * | 1993-06-01 | 1998-05-01 | Ono Pharmaceutical Co | Derivados del acido pentanoico. |
JPH0782146A (ja) * | 1993-07-23 | 1995-03-28 | Sagami Chem Res Center | 抗痴呆薬 |
JPH07285911A (ja) * | 1994-04-20 | 1995-10-31 | New Japan Chem Co Ltd | 脂肪族モノカルボン酸組成物 |
JPH0853351A (ja) * | 1994-08-11 | 1996-02-27 | Sagami Chem Res Center | 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤 |
JP3032447B2 (ja) * | 1995-04-24 | 2000-04-17 | 小野薬品工業株式会社 | 光学活性な2−プロピルオクタン酸の製造方法 |
JP3084345B2 (ja) * | 1995-04-26 | 2000-09-04 | 小野薬品工業株式会社 | 光学活性な2−プロピルオクタン酸の製造方法 |
JPH10298072A (ja) | 1997-04-17 | 1998-11-10 | Panacea Biotec Ltd | 非ステロイド性抗炎症剤の遷移金属錯体 |
US6043223A (en) * | 1997-11-12 | 2000-03-28 | The Regents Of The University Of California | Enhanced opening of abnormal brain tissue capillaries |
TWI268921B (en) * | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
US6552082B2 (en) * | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
JP4706950B2 (ja) * | 2000-07-18 | 2011-06-22 | 小野薬品工業株式会社 | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
JP4178405B2 (ja) * | 2001-07-18 | 2008-11-12 | 小野薬品工業株式会社 | 脳虚血疾患治療剤 |
-
2004
- 2004-10-01 CA CA002540670A patent/CA2540670A1/en not_active Abandoned
- 2004-10-01 AU AU2004277826A patent/AU2004277826B2/en not_active Ceased
- 2004-10-01 EP EP04792177A patent/EP1669065B1/en not_active Expired - Lifetime
- 2004-10-01 TW TW093129802A patent/TW200519080A/zh unknown
- 2004-10-01 NZ NZ546231A patent/NZ546231A/en unknown
- 2004-10-01 KR KR1020067008535A patent/KR101144553B1/ko not_active IP Right Cessation
- 2004-10-01 BR BRPI0415001-5A patent/BRPI0415001A/pt not_active Application Discontinuation
- 2004-10-01 RU RU2006114835/15A patent/RU2388467C2/ru not_active IP Right Cessation
- 2004-10-01 US US10/574,477 patent/US8053599B2/en not_active Expired - Fee Related
- 2004-10-01 WO PCT/JP2004/014892 patent/WO2005032536A1/ja active Application Filing
- 2004-10-01 ES ES04792177T patent/ES2390055T3/es not_active Expired - Lifetime
- 2004-10-01 SG SG200807282-9A patent/SG146687A1/en unknown
- 2004-10-01 MX MXPA06003533A patent/MXPA06003533A/es not_active Application Discontinuation
- 2004-10-01 JP JP2005514507A patent/JP4715515B2/ja not_active Expired - Fee Related
- 2004-10-01 CN CN2004800361288A patent/CN1889942B/zh not_active Expired - Fee Related
-
2006
- 2006-03-30 IL IL174655A patent/IL174655A0/en unknown
- 2006-03-31 ZA ZA200602690A patent/ZA200602690B/en unknown
- 2006-03-31 NO NO20061460A patent/NO20061460L/no not_active Application Discontinuation
- 2006-04-03 EC EC2006006477A patent/ECSP066477A/es unknown
- 2006-04-26 IS IS8430A patent/IS8430A/is unknown
- 2006-05-02 MA MA28991A patent/MA28142A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200519080A (en) | 2005-06-16 |
CA2540670A1 (en) | 2005-04-14 |
NZ546231A (en) | 2009-09-25 |
MXPA06003533A (es) | 2006-06-08 |
ECSP066477A (es) | 2007-03-29 |
US8053599B2 (en) | 2011-11-08 |
NO20061460L (no) | 2006-07-03 |
AU2004277826B2 (en) | 2010-05-27 |
WO2005032536A1 (ja) | 2005-04-14 |
EP1669065A1 (en) | 2006-06-14 |
EP1669065A4 (en) | 2009-12-16 |
JPWO2005032536A1 (ja) | 2006-12-14 |
US20070105956A1 (en) | 2007-05-10 |
SG146687A1 (en) | 2008-10-30 |
EP1669065B1 (en) | 2012-07-18 |
KR101144553B1 (ko) | 2012-05-11 |
KR20060099525A (ko) | 2006-09-19 |
RU2388467C2 (ru) | 2010-05-10 |
MA28142A1 (fr) | 2006-09-01 |
IL174655A0 (en) | 2006-08-20 |
ES2390055T3 (es) | 2012-11-06 |
CN1889942B (zh) | 2010-12-15 |
AU2004277826A1 (en) | 2005-04-14 |
IS8430A (is) | 2006-04-26 |
RU2006114835A (ru) | 2007-11-20 |
ZA200602690B (en) | 2007-07-25 |
CN1889942A (zh) | 2007-01-03 |
JP4715515B2 (ja) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240238382A1 (en) | URI Agonist/Vasodilator | |
Altier et al. | Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine | |
Lawand et al. | Amino acid release into the knee joint: key role in nociception and inflammation | |
JP7413315B2 (ja) | Gip/glp1アゴニスト組成物 | |
ECSP066477A (es) | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo | |
Townsend et al. | Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats | |
CA2663857C (en) | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief | |
BRPI0518460A2 (pt) | mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia' | |
Martens et al. | Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers | |
CN109069590A (zh) | 包含聚山梨酯80的胰岛素制剂 | |
EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
DK2662073T3 (en) | Octreotide injection | |
ATE539761T1 (de) | Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion | |
KR20190035927A (ko) | 안구 내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조방법 | |
Maisonneuve et al. | Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine | |
BR112021007083A2 (pt) | tratamento de doença neurológica com zilucoplan | |
ECSP066476A (es) | Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo | |
TW201936191A (zh) | 持續釋放輸送丁基原啡因之藥學組合物 | |
US11040007B2 (en) | Injection composition containing acetaminophen | |
Hildebrand et al. | Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system | |
US9375407B2 (en) | Dimethyl trisulfide as a cyanide antidote | |
US10632261B2 (en) | Self-admixing disposable hypodermic needle | |
WO2009157010A1 (en) | An intravenous drug delivery system | |
PT2262493E (pt) | Métodos de tratamento empregando infusão contínua prolongada de belinostat | |
DeTolla et al. | Subcutaneous Implants of Buprenorphine‐Cholesterol‐Triglyceride Powder in Mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |